Briefly, FreSHtracer was synthesized by mixing a coumarin-3-carbaldehyde derivative and 2-cyano- N,N -dimethylacetamide at 60 C for 2 days, and purified using SiO 2 chromatography [19]
The PlexusDx Precision Peptide Genetic Test identifies variants in key genesincluding GLP1R (rs6923761), MC4R (rs17782313), FTO (rs9939609), and GIPR (rs1800437)that influence GLP-1 sensitivity and metabolic predisposition
Based on the typical UK regulatory pathway, the most realistic timeline is: Late 2026 / early 2027: Eli Lilly expected to submit regulatory filings to the FDA and MHRA following completion of the remaining TRIUMPH Phase 3 readouts Late 2027 to mid-2028: Possible MHRA marketing authorisation, allowing private UK prescribing 2028 to 2029 onwards: Possible NHS availability following a NICE technology appraisal and NHS commissioning decisions Timelines may differ across the four UK nations, as Scotland, Wales, and Northern Ireland assess medicines separately through the Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group (AWMSG), and the Department of Health Northern Ireland respectively
CJC-1295 and Ipamorelin also help by boosting growth hormone, which supports fat metabolism and lean muscle retention.
Based on the available data, the peptide is well tolerated in short-term studies
